FDA rejects Singulair-Claritin combination

Apr 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Asthma drug prevents spread of breast cancer: study

Nov 03, 2010

A drug commonly used in Japan and Korea to treat asthma has been found to stop the spread of breast cancer cells traditionally resistant to chemotherapy, according to a new study led by St. Michael's pathologist Dr. Gerald ...

Munich researchers discover key allergy gene

Aug 22, 2008

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment of the Technische Universität München, scientists at the Helmholtz Zentrum München have pinpointed a major ...

Hay fever can send work productivity down the drain

Apr 26, 2007

Employers can blame hay fever for the loss of millions of hours of work productivity this spring. A new study of nearly 600 people with hay fever symptoms, including sneezing, watery eyes and runny and itchy noses, found ...

Recommended for you

Determine patient preferences by means of conjoint analysis

3 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0